Epstein-Barr Virus Panel

Message

Sendout, Mayo test code: SEBV

Test Code

LAB863

Alias/See Also

Anti EBV Serology
E. B. (Epstein-Barr) Virus
EBNA (Epstein-Barr Nuclear Antigen)
EBV (Epstein-Barr Virus) Battery
EBV (Epstein-Barr Virus) Panel
EBV (Epstein-Barr Virus)
EBV Panel, Serum
Epstein Barr Virus
Epstein-Barr Virus AB
Epstein-Barr Virus Battery
Epstein-Barr Virus Panel
VCA (Viral Capsid Antigen) IgG and IgM
Viral Capsid Antigen (VCA) Titer
Infectious Mononucleosis
EBV Ab, Serum
SEBV

CPT Codes
86664, 86665x2

Preferred Specimen

1 mL serum from a gold serum gel tube

Minimum Volume

0.6 mL

Other Acceptable Specimens

Red tube

Instructions

Centrifuge and aliquot serum into a plastic vial.

Transport Container

Plastic vial

Transport Temperature

Room Temperature

Specimen Stability

Refrigerated (preferred): 14 days
Frozen: 14 days

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: Reject
Heat-inactivated specimen: Reject

Methodology
Immunoassay(IA)

FDA Status
Approved

Setup Schedule

Tues-Sat

Report Available

1-3 days

Limitations

Specimens collected too early during the course of the disease may not contain detectable antibody to Epstein-Barr virus (EBV). Another specimen collected 1 to 2 weeks later may be required.

Test results should be evaluated in relation to patient symptoms, clinical history, and other laboratory findings.

The timing of the appearance of IgG antibodies to viral capsid antigen (VCA) or Epstein-Barr nuclear antigen (EBNA) or IgM antibodies to VCA is subject to variations among individuals and serological assays.

This assay's performance characteristics with immunosuppressed individuals, newborns, cord blood, or matrices other than human serum have not been established.

Assay performance characteristics have not been established for the diagnosis of nasopharyngeal carcinoma, Burkitt lymphoma, and other EBV-associated lymphomas.

Anti-VCA-specific IgG may compete with IgM for binding sites, leading to false-negative results. Rheumatoid factor (RF), in the presence of specific IgG, may contribute to false-positive results. The absorbent in the VCA IgM diluent is intended to neutralize the effects of RF and specific IgG. Studies have shown that the absorbent was able to neutralize up to 98% of the activity in a specimen known to contain 3328 IU/mL of RF activity.

Testing for VCA IgM should not be performed as a screening procedure on the general population. The predictive value of positive or negative results depends on the pretest likelihood of Epstein-Barr-associated disease being present. Testing should only be performed when clinical evidence suggests the diagnosis of this syndrome.

Reference Range

Included with report

Clinical Significance

Diagnosing infectious mononucleosis when a mononucleosis screening procedure is negative and infectious mononucleosis or a complication of Epstein-Barr virus infection is suspected.

This assay is not intended for viral isolation or identification.

Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota

Additional Information
Epstein-Barr Virus (EBV) Antibody Profile, Serum

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.